Skip to main content

Advertisement

SpringerLink
Log in

Neuroleptic-Associated Hyperprolactinemia: Clinical Manifestations and Effects on Sexual Function

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objectives. To study the clinical manifestations of neuroleptic-associated hyperprolactinemia (NAH) and its influences on sexual functions in patients with mental disorders and prolonged treatment with neuroleptics. Materials and methods. A total of 244 patients were investigated – 140 women and 104 men – with mental disorders and receiving treatment with neuroleptics. Blood prolactin and bioactive prolactin levels were estimated in all patients, these assays in some patients being accompanied by determination of gonadotropins, sex hormones, and sex steroid-binding globulin. Side effects of neuroleptics were assessed using the UKU Side Effects Rating Scale. Impairments to sexual functions were assessed using the Psychotropic-Related Sexual Dysfunction Questionnaire. Results and conclusions. Asymptomatic NAH was detected in 16% of women and 37% of men. In women, NAH led to impairments in the menstrual cycle – oligo- or amenorrhea – and galactorrhea. NAH was accompanied by sexual impairments in both in both men and women. In patients of both genders, NAH was associated with weakening of libido and deterioration of quality of life due to sexual impairment. In addition, women with NAH had delayed onset of orgasm and vaginal dryness during sexual intercourse. In men, NAH was also associated with erectile dysfunction. In contrast to tumor-related and idiopathic hyperprolactinemia, NAH was not accompanied by increases in body weight and the development of obesity, or the development of hypogonadism in patients of either gender.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A. Wieck and P. Haddad, “Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences,” Brit. J. Psychiatry, 182, 199–204 (2003), doi: https://doi.org/10.1192/bjp.182.3.199.

    Article  CAS  Google Scholar 

  2. C. Canuso, J. Goldstein, J. Wojcik, et al., “Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder,” Psychiatry Res., 111, No. 1, 11–20 (2002), doi: https://doi.org/10.1016/S0165-1781(02)00123-3.

    Article  CAS  PubMed  Google Scholar 

  3. S. Smith, M. Wheeler, R. Murray, et al., “The effects of antipsychotic- induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis,” J. Clin. Psychopharmacol., 22, No. 2, 109–114 (2002), doi:https://doi.org/10.1097/00004714-200204000-00002.

    Article  CAS  PubMed  Google Scholar 

  4. E. Johnsen, R. Kroken, M. Abaza, et al., “Antipsychotic-induced hyperprolactinemia: a cross-sectional survey,” J. Clin. Psychopharmacol., 28, No. 6, 686–690 (2008), doi: https://doi.org/10.1016/j.schres.2007.12.383.

    Article  CAS  PubMed  Google Scholar 

  5. T. Baptista, M. Molina, J. Martinez, et al., “Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation,” Pharmacopsychiatry, 30, No. 6, 256–262 (1997), doi:https://doi.org/10.1055/s-2007-979503.

    Article  CAS  PubMed  Google Scholar 

  6. B. Kinon, J. Gilmore, H. Liu, et al., “Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone,” Psychoneuroendocrinology, 28, Suppl. 2, 55–68 (2003), doi:https://doi.org/10.1016/s0306-4530(02)00127-0.

  7. D. Prentice and J. Deakin, “Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women,” Schizophr. Res., 6, 114–118 (1992), doi: https://doi.org/10.1016/0920-9964(92)90144-t.

    Article  Google Scholar 

  8. J. Eberhard, E. Lindstrom, M. Holstad, et al., “Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders,” Acta Psychiatr. Scand., 115, No. 4, 268–276 (2007), doi: https://doi.org/10.1111/j.1600-0447.2006.00897.x.

    Article  CAS  PubMed  Google Scholar 

  9. M. Neovius, J. Eberhard, E. Lindstrom, et al., “Weight development in patients treated with risperidone: a 5-year naturalistic study,” Acta. Psychiatr. Scand., 115, No. 4, 277–285 (2007), doi: https://doi.org/10.1111/j.1600-0447.2006.00899.x.

    Article  CAS  PubMed  Google Scholar 

  10. K. Melkersson, K. Berinder, and A. Hulting, “Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses,” Neuro. Endocrinol. Lett., 32, No. 4, 428–436 (2011).

    CAS  PubMed  Google Scholar 

  11. T. Baptista, A. Lacruz, T. Meza, et al., “Antipsychotic drugs and obesity: is prolactin involved?” Can. J. Psychiatry, 46, No. 9, 829–834 (2001).

    Article  CAS  PubMed  Google Scholar 

  12. V. O’Keane and A. Meaney, “Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?” J. Clin. Psychopharmacol., 25, No. 1, 26–31 (2005), doi: https://doi.org/10.1097/01.jcp.0000150223.31007.e0.

    Article  PubMed  Google Scholar 

  13. T. Kishimoto, K. Watanabe, and N. Shimada, “Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia,” J. Clin. Psychiatry, 69, No. 3, 385–391 (2008), doi: https://doi.org/10.4088/jcpv69n0307.

    Article  CAS  PubMed  Google Scholar 

  14. N. Bergemann, C. Mundt, and P. Parzer, “Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics,” Schizophr. Res., 73, No. 2–3, 357–366 (2005), doi: https://doi.org/10.1016/j.schres.2004.06.013.

    Article  PubMed  Google Scholar 

  15. B. Kinon, J. Gilmore, H. Liu, et al., “Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone,” Psychoneuroendocrinology, 28, Suppl. 2, 55–68 (2003), doi: https://doi.org/10.1016/s0306-4530(02)00127-0.

  16. Y. Kaneda, “The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia,” Clin. Neuropharmacol., 26, No. 4, 182–184 (2003), doi: https://doi.org/10.1097/00002826-200307000-00006.

    Article  CAS  PubMed  Google Scholar 

  17. A. Serretti and A. Chiesa, “A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics,” Int. Clin. Psychopharmacol., 26, No. 3, 130–140 (2011), doi: https://doi.org/10.1097/yic.0b 013e328.341e434.

  18. H. Knegtering, R. Boscha, S. Casteleina, et al., “Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?” Psychoneuroendocrinology, 33, 711–71756 (2008), doi: https://doi.org/10.1016/j.psyneuen.2008.02.008.

    Article  CAS  PubMed  Google Scholar 

  19. M. Rettenbacher, A. Hofer, C. Ebenbichler, et al., “Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment,” J. Clin. Psychopharmacol., 30, No. 6, 711–715 (2010), doi: https://doi.org/10.1097/jcp.0b013e3181faf0e3.

    Article  CAS  PubMed  Google Scholar 

  20. R. Knegtering, S. Castelein, H. Bous, et al., “A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning,” J. Clin. Psychopharmacol., 24, No. 1, 56–61 (2004), doi: https://doi.org/10.1097/01.jcp.0000106220.36344.04.

    Article  CAS  PubMed  Google Scholar 

  21. E. Johnsen, R. Kroken, E. Loberg, et al., “Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: A cross-sectional study,” Adv. Urol., (2011), doi: https://doi.org/10.1155/2011/686924

  22. S. M. Smith, V. O’Keane, R. Murray, et al., “Sexual dysfunction in patients taking conventional antipsychotic medication,” Br. J. Psychiatry, 181, 49–55 (2002), doi: https://doi.org/10.1016/s0920-9964(00)90844-2

  23. G. A. Mel’nichenko, N. P. Goncharov, Dzeranova L. K, et al., “Clinical and laboratory aspects of studies of prolactin isoforms by PEG precipitation and ultrafiltration,” Prob. Endokrinol., No. 1, 19–25 (2010), doi: https://doi.org/10.14341/probl201056119-25.

  24. P. Nakonezny, M. Byerly, and A. Rush, “The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine,” J. Sex Marital Ther., 33, No. 3, 203–216 (2007), doi:https://doi.org/10.1080/00926230701267829.

    Article  PubMed  Google Scholar 

  25. J. Westheide, G. Cvetanovska, C. Albrecht, et al., “Prolactin, subjective wellbeing and sexual dysfunction: an open label observational study comparing quetiapine with risperidone,” J. Sex Med., 5, No. 12, 2816–2826 (2008), doi: https://doi.org/10.1111/j.1743-6109.2008.00859.x.

    Article  CAS  PubMed  Google Scholar 

  26. B. Konarzewska, S. Wołczyński, A. Szulc, et al., “Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia,” Psychoneuroendocrinology, 34, No. 1, 129–139 (2009), doi: https://doi.org/10.1016/j.psyneuen.2008.08.015.

    Article  CAS  PubMed  Google Scholar 

  27. N. Yasui-Furukori, A. Fujii, N. Sugawara, et al., “No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics,” Hum. Psychopharmacol., 27, No. 1, 82–89 (2012), doi: https://doi.org/10.1002/hup.1275.

    Article  CAS  PubMed  Google Scholar 

  28. O. A. Yunilainen, E. G. Starostina, L. K. Dzeranova, et al., “Epidemiological characteristics of neuroleptic-associated hyperprolactinemia,” Sovremen. Terap. Psikhiatr. Nevrol., No. 4, 4–9 (2014).

    Google Scholar 

  29. O. Lingjaerde, U. Ahlfors, P. Bech, et al., “The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients,” Acta Psychiatr. Scand., 334, 1–100 (1987), doi: https://doi.org/10.1111/j.1600-0447.1987.tb10566.x

    Article  CAS  Google Scholar 

  30. A. L. Montejo and F. Rico-Villademoros, “Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders,” J. Sex Marital Ther., 34, No. 3, 227–239 (2008), doi: https://doi.org/10.1080/00926230701866125.

    Article  PubMed  Google Scholar 

  31. P. Malik, G. Kemmler, M. Hummer, et al., “Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial,” J. Clin. Psychopharmacol., 31, No. 3, 274–280 (2011), doi: https://doi.org/10.1097/jcp.b013e3182199bcc.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scientific Center for Mental Health, Moscow, Russia

    O. A. Yunilainen, L. K. Dzeranova & I. I. Dedov

  2. Vladimirskii Moscow Regional Research Institute, Moscow, Russia

    E. G. Starostina

  3. Moscow Research Institute of Psychiatry, Serbskii Federal Medical Research Center of Psychiatry and Narcology, Moscow, Russia

    E. G. Starostina

  4. Alekseev Psychiatric Clinical Hospital No. 1, Moscow, Russia

    G. N. Kudryashkina & L. G. Kessel’man

  5. Russian Postgraduate Medical Academy, Moscow, Russia

    P. A. Baranov

Authors
  1. O. A. Yunilainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. G. Starostina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. K. Dzeranova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. N. Kudryashkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. G. Kessel’man
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. A. Baranov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. I. Dedov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. A. Yunilainen.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 116, No. 11, Iss. 1, pp. 17–25, November, 2016.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yunilainen, O.A., Starostina, E.G., Dzeranova, L.K. et al. Neuroleptic-Associated Hyperprolactinemia: Clinical Manifestations and Effects on Sexual Function. Neurosci Behav Physi 48, 358–366 (2018). https://doi.org/10.1007/s11055-018-0571-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-018-0571-y

Keywords

Search

Navigation